New investor files pharma IPR as patent validity challenges look like being an increasing trend in 2016
Another investment group has filed an inter partes review (IPR) against a pharmaceutical patent, joining the small band of investors that have started to pose a significant challenge to leading drugmakers in the US. The IPR was filed just before…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.